Cantor Fitzgerald Reiterates Overweight on Kura Oncology
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Kura Oncology (NASDAQ:KURA).
August 09, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Li Watsek has reiterated an Overweight rating on Kura Oncology (NASDAQ:KURA).
The reiteration of an Overweight rating by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100